Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices 55831 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $126,400,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: September 2, 2010. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. 2010–22785 Filed 9–13–10; 8:45 am] 

BILLING CODE 4410–09–P 

OFFICE OF NATIONAL DRUG 

CONTROL POLICY 

Appointment of Members of Senior 

Executive Services Performance 

Review Board. 

AGENCY: Office of National Drug Control 

Policy [ONDCP]. 

ACTION: Notice of Appointments. 

Heading: Appointment of Members of 

Senior Executive Services Performance 

Review Board. 

SUMMARY: The following persons have 

been appointed to the ONDCP Senior 

Executive Service Performance Review 

Board: Dr. Terry Zobeck, Ms. Martha 

Gagne, Ms. Christine Leonard, and Mr. 

Patrick Ward. 

FOR FURTHER INFORMATION CONTACT: 

Please direct any questions to Linda V. 

Priebe, Deputy General Counsel (202) 

395–6622, Office of National Drug 

Control Policy, Executive Office of the 

President, Washington, DC 20503. 

Linda V. Priebe, 

Deputy General Counsel. 

[FR Doc. 2010–22794 Filed 9–13–10; 8:45 am] 

BILLING CODE 3180–02–P 

NUCLEAR REGULATORY 

COMMISSION 

Advisory Committee on the Medical 

Uses of Isotopes: Call for Nominations 

AGENCY: U.S. Nuclear Regulatory 

Commission. 

ACTION: Call for Nominations. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) is advertising for 

nominations for the patients’ rights 

advocate position on the Advisory 

Committee on the Medical Uses of 

Isotopes (ACMUI). Nominees should 

have professional or personal 

experience with or knowledge about 

patient advocacy. Also, involvement or 

leadership with patient advocacy 

organizations is preferred. 

DATES: Nominations are due on or 

before November 15, 2010. 

NOMINATION PROCESS: Submit an 

electronic copy of resume or curriculum 

vitae, along with a cover letter, to Ms. 

Ashley Cockerham, ashley.

cockerham@nrc.gov. The cover letter 

should describe the nominee’s current 

involvement with patients’ rights 

advocacy and express the nominee’s 

interest in the position. Please ensure 

that resume or curriculum vitae 

includes the following information, if 

applicable: education; certification; 

professional association membership 

and committee membership activities; 

and number of years, recentness, and 

type of setting for patient advocacy. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Ashley Cockerham, U.S. Nuclear 

Regulatory Commission, Office of 

Federal and State Materials and 

Environmental Management Programs; 

(240) 888–7129; ashley.cockerham@nrc.

gov. 

SUPPLEMENTARY INFORMATION: The 

patients’ rights advocate provides 

advice to NRC staff on patients’ issues 

associated with the regulation of 

medical applications of byproduct 

material. This advice includes ensuring 

patients’ rights are represented during 

the development and implementation of 

NRC medical-use policy. This 

individual is appointed based on his or 

her professional and personal 

experience with and/or knowledge 

about patient advocacy, involvement 

and/or leadership with patient advocacy 

organizations, and other information 

obtained in letters or during the 

selection process. Nominees should 

have the demonstrated ability to 

establish effective work relationships 

with peers and implement successful 

approaches to problem solving and 

conflict resolution. ACMUI members 

currently serve a four-year term and 

may be considered for reappointment to 

an additional term. The current 

membership is comprised of the 

following professionals: (a) Nuclear 

medicine physician; (b) nuclear 

cardiologist; (c) nuclear medicine 

physicist; (d) therapy medical physicist; 

(e) radiation safety officer; (f) nuclear 

pharmacist; (g) two radiation 

oncologists; (h) patients’ rights 

advocate; (i) Food and Drug 

Administration representative; (j) 

Agreement State representative; (k) 

health care administrator; and (l) 

diagnostic radiologist. For additional 

information about membership on the 

ACMUI, visit the ACMUI Membership 

Web page, http://www.nrc.gov/aboutnrc/regulatory/advisory/acmui/

membership.html. 

Nominees must be U.S. citizens and 

be able to devote approximately 160 

hours per year to Committee business. 

Members are expected to attend semiannual meetings in Rockville, Maryland 

and to participate in teleconferences, as 

needed. Members who are not Federal 

employees are compensated for their 

service. In addition, these members are 

reimbursed for travel and 

correspondence expenses. Full-time 

Federal employees are reimbursed for 

travel expenses only. 

Security Background Check: The 

selected nominee will undergo a 


jlentini on DSKJ8SOYB1PROD with NOTICES